Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05812781 · ClinicalTrials.gov registry record · Phase 2
A Study to Evaluate VTX2735 in Patients With Cryopyrin-associated Periodic Syndrome
A Phase 2 study, sponsored by Zomagen Biosciences.
- Completed
- Registry status
- Phase 2
- Development phase
- 7
- Enrollment target
NCT05812781 is a Phase 2 study that has completed, run by Zomagen Biosciences. The registered enrollment target is 7 participants.
The verdict
NCT05812781, a Phase 2 study, has completed, sponsored by Zomagen Biosciences.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 7 participants
- Enrollment target
Study Summary
This is a study to understand if taking VTX2735 is safe and effective in participants diagnosed with Cryopyrin-Associated Period Syndrome (CAPS). Approximately 10 patients will take VTX2735 Dose A or VTX2735 Dose B. The study consists of a screening/washout period of up to 28 weeks, a 2 week treatment period, a treatment withdrawal period of up to 2 weeks, another 2 week treatment period, and a 4 week follow up period. The maximum length of treatment is 4 weeks.
Interventions
- DRUG VTX2735
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 7 participants |
| Start Date | 2023-03-18 |
| Est. Completion | 2024-03-06 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05812781
The ClinicalTrials.gov registry entry for NCT05812781 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 7 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Zomagen Biosciences, which has 4 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which VTX2735 is the first listed.
NCT05812781 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05812781 about?
NCT05812781 is a clinical study titled "A Study to Evaluate VTX2735 in Patients With Cryopyrin-associated Periodic Syndrome". This is a study to understand if taking VTX2735 is safe and effective in participants diagnosed with Cryopyrin-Associated Period Syndrome (CAPS). Approximately 10 patients will take VTX2735 Dose A or VTX2735 Dose B. The study consists of a screening/washout period of up to 28 weeks, a 2 week treatm...
What is the current status of trial NCT05812781?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 7 participants. The study started on 2023-03-18. Estimated completion is 2024-03-06.
What interventions are being tested in trial NCT05812781?
The interventions under investigation include: VTX2735 (DRUG).
Who is sponsoring clinical trial NCT05812781?
This trial is sponsored by Zomagen Biosciences, which has 4 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.